Ivax breath-activated HFA albuterol “approvable”
Executive Summary
Ivax' breath-activated hydrofluoroalkane-propelled albuterol gets "approvable" letter from FDA, the company announces July 7. Ivax markets the breath-activated device as Easi-Breathe in Europe. Members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested delaying a chlorofluorocarbon ban to allow time for Ivax' and Sepracor's Xopenex HFA (levalbuterol) products to reach market (1"The Pink Sheet" June 21, 2004, p. 42)...
You may also be interested in...
Albuterol Transition To CFC-Free: Increased Cost Could Affect Patient Access
Increases in cost of albuterol inhalers due to the transition from chlorofluorocarbons to non-ozone depleting substances could affect patient access, members of FDA's Pulmonary-Allergy Drugs Advisory Committee suggested
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.